Bausch Health (BHC) Xifaxan Competitor Arrives - Wells Fargo's Maris

Wells Fargo analyst David Maris weighed in on Bausch Health Companies (NYSE: BHC) after a new competitor for its largest product, Xifaxan, was approved after the close on Friday.

Maris estimates that Xifaxan represents approximately 15% of total BHC sales and a higher proportion of EBITDA.

"We believe this is the first step toward an eventual significant slowdown and potentially a decline in Xifaxan revenues," he commented.

The firm reiterated an Underperform rating and price target of $9.00 on BHC.

For an analyst ratings summary and ratings history on Bausch Health Companies click here. For more ratings news on Bausch Health Companies click here.

Shares of Bausch Health Companies closed at $25.33 yesterday.

You May Also Be Interested In

• AMD (AMD) to offer senior notes in four parts
• UBS Reiterates Buy Rating on HF Sinclair (DINO)
• McGraw Hill (MH) PT Raised to $15 at UBS